These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37641544)
1. First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial. Kim HR; Sugawara S; Lee JS; Kang JH; Inui N; Hida T; Lee KH; Yoshida T; Tanaka H; Yang CT; Nishio M; Ohe Y; Tamura T; Yamamoto N; Yu CJ; Akamatsu H; Takahashi S; Nakagawa K Cancer Med; 2023 Aug; 12(16):17061-17067. PubMed ID: 37641544 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Sugawara S; Lee JS; Kang JH; Kim HR; Inui N; Hida T; Lee KH; Yoshida T; Tanaka H; Yang CT; Nishio M; Ohe Y; Tamura T; Yamamoto N; Yu CJ; Akamatsu H; Namba Y; Sumiyoshi N; Nakagawa K Ann Oncol; 2021 Sep; 32(9):1137-1147. PubMed ID: 34139272 [TBL] [Abstract][Full Text] [Related]
3. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Kanda S; Ohe Y; Goto Y; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Yamamoto T; Tamura T Cancer Sci; 2020 Jun; 111(6):1933-1942. PubMed ID: 32277531 [TBL] [Abstract][Full Text] [Related]
4. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877 [TBL] [Abstract][Full Text] [Related]
5. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874 [TBL] [Abstract][Full Text] [Related]
7. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Argiris A; Lee JW; Stevenson J; Sulecki MG; Hugec V; Choong NW; Saltzman JN; Song W; Hansen RM; Evans TL; Ramalingam SS; Schiller JH Ann Oncol; 2017 Dec; 28(12):3037-3043. PubMed ID: 28950351 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab biosimilar candidate TAB008 compared to Avastin Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042 [TBL] [Abstract][Full Text] [Related]
9. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. Bylicki O; Tomasini P; Radj G; Guisier F; Monnet I; Ricordel C; Bigay-Game L; Geier M; Chouaid C; Daniel C; Swalduz A; Toffart AC; Doubre H; Peloni JM; Moreau D; Subtil F; Grellard JM; Castera M; Clarisse B; Martins-Lavinas PH; Decroisette C; Greillier L; Eur J Cancer; 2023 Apr; 183():38-48. PubMed ID: 36801605 [TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473 [TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Cohen MH; Gootenberg J; Keegan P; Pazdur R Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060 [TBL] [Abstract][Full Text] [Related]
14. An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. Yadav A; Malik PS; Khurana S; Jain D; Vishnubhatla S; Yadav M; Pathy S; Mohan A; Kumar L Oncology; 2021; 99(6):389-396. PubMed ID: 33735884 [TBL] [Abstract][Full Text] [Related]
15. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067 [TBL] [Abstract][Full Text] [Related]
16. Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study. Omori M; Minegishi Y; Uruga H; Fukuizumi A; Isobe K; Izumi S; Koyama R; Bando M; Sugiyama H; Takahashi K; Gemma A; Homma S; Sugiyama Y; Kishi K Respir Investig; 2023 Sep; 61(5):625-631. PubMed ID: 37441903 [TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650 [TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797 [TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Cortot AB; Audigier-Valette C; Molinier O; Le Moulec S; Barlesi F; Zalcman G; Dumont P; Pouessel D; Poulet C; Fontaine-Delaruelle C; Hiret S; Dixmier A; Renault PA; Becht C; Raffy O; Dayen C; Mazieres J; Pichon E; Langlais A; Morin F; Moro-Sibilot D; Besse B Eur J Cancer; 2020 May; 131():27-36. PubMed ID: 32276179 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Niho S; Kunitoh H; Nokihara H; Horai T; Ichinose Y; Hida T; Yamamoto N; Kawahara M; Shinkai T; Nakagawa K; Matsui K; Negoro S; Yokoyama A; Kudoh S; Kiura K; Mori K; Okamoto H; Sakai H; Takeda K; Yokota S; Saijo N; Fukuoka M; Lung Cancer; 2012 Jun; 76(3):362-7. PubMed ID: 22244743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]